← Back to Clinical Trials
Recruiting NCT02022943

NCT02022943 Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02022943
Status Recruiting
Phase
Sponsor Banner Health
Condition Alzheimer's Disease
Study Type OBSERVATIONAL
Enrollment 500,000 participants
Start Date 2012-05
Primary Completion 2030-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 110 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500,000 participants in total. It began in 2012-05 with a primary completion date of 2030-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The Alzheimer's Prevention Registry (www.endALZnow.org) will collect contact and demographic information on individuals. The objective is to provide information the latest news and advances in Alzheimer's prevention research, and to inform enrollees about research studies in their community. Enrolled individuals will receive regular email communications. As research studies become available, individuals will be notified via email with information as to how proceed should they be interested. Registry enrollees are under no obligation to participate in a research study. Study opportunities may include surveys, healthy lifestyle interventions (e.g., diet, exercise), memory \& thinking tests, brain scans, and investigational drug trials. To join the Registry, please visit www.endALZnow.org

Eligibility Criteria

Inclusion Criteria: * Must be able to accept the Alzheimer's Prevention Registry website terms and conditions Exclusion Criteria: * None

Contact & Investigator

Central Contact

Nellie High, MA

✉ info@endALZnow.org

📞 1-888-STOP-ALZ

Principal Investigator

Jessica Langbaum, PhD

PRINCIPAL INVESTIGATOR

Banner Alzheimer's Institute

Frequently Asked Questions

Who can join the NCT02022943 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02022943 currently recruiting?

Yes, NCT02022943 is actively recruiting participants. Contact the research team at info@endALZnow.org for enrollment information.

Where is the NCT02022943 trial being conducted?

This trial is being conducted at Phoenix, United States.

Who is sponsoring the NCT02022943 clinical trial?

NCT02022943 is sponsored by Banner Health. The principal investigator is Jessica Langbaum, PhD at Banner Alzheimer's Institute. The trial plans to enroll 500,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology